, Volume 43, Issue 2, pp 141–145 | Cite as

Treatment of Breast Cancer in the 1990s

What Does the Future Hold?
  • Roy B. Jones
  • Elizabeth J. Shpall
Leading Article


Breast Cancer Metastatic Breast Cancer Axillary Lymph Node Advanced Breast Cancer Celiprolol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonadonna G. Conceptual and practical advances in the management of breast cancer. Journal of Clinical Oncology 7: 1380–1397, 1987Google Scholar
  2. Bonadonna G, Rossi A, Valagussa P. Adjuvant CMF chemotherapy in operable breast cancer ten years later. World Journal of Surgery 9: 707–713, 1985PubMedCrossRefGoogle Scholar
  3. Bronchud MH, Howell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. British Journal of Cancer 60: 121–125, 1989PubMedCrossRefGoogle Scholar
  4. Buckley MM-T, Goa KL. Tamoxifen: A reapprasial of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37: 451–490, 1989PubMedCrossRefGoogle Scholar
  5. Carmo-Pereira J, Costa FO, Henrigues E, et al. Advanced breast carcinoma: a comaprison of two dose levels of adriamycin. Abstract. Proceedings of the American Society of Clinical Oncology 5: 56, 1986Google Scholar
  6. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. New England Journal of Medicine 317: 1490–1495, 1987PubMedCrossRefGoogle Scholar
  7. Decker DA, Ahmann DL, Bisel HF, Edmonson JH, et al. Complete responders to chemotherapy in metastatic breast cancer. Journal of the American Medical Association 242: 2075–2079, 1979PubMedCrossRefGoogle Scholar
  8. Dicke KA, Vellekoop L, Zander A, Jagganath S, Poytiron C, et al. Autologous transplantation in acute leukemia. Survey and Synthesis of Pathology Research 4: 84–96, 1985PubMedGoogle Scholar
  9. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi G, Horowitz LJ, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. Journal of Clinical Oncology 8: 1207–1216, 1990PubMedGoogle Scholar
  10. Fisher B, Fisher ER. The barrier function of the lymph node to tumor cells and erythrocytes. II. Normal nodes. Cancer 20: 1907–1913, 1967PubMedCrossRefGoogle Scholar
  11. Fisher B, Slack NH, Cooperating Investigators. Number of lymph nodes examined and the prognosis of breast cancer. Surgery Gynecology and Obstetrics 131: 79–88, 1970Google Scholar
  12. Hollingshead LM, Goa KL. Récombinant granulocyte colonystimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42: 300–330, 1991PubMedCrossRefGoogle Scholar
  13. Hortobagyi GN, Frye D, Buzdar AU, et al. Complete remissions in metastatic breast cancer. Abstract. Proceedings of the American Society of Clinical Oncology 7: 37, 1988Google Scholar
  14. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. Journal of Clinical Oncology 4: 1162–1170, 1986PubMedGoogle Scholar
  15. Jones RB, Holland JF, Bhardwaj S, et al.: A phase I–II study of intensive-dose adriamycin for advanced breast cancer. Journal of Clinical Oncology 5: 172–177, 1987aPubMedGoogle Scholar
  16. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. American Journal of Clinical Oncology 10: 387–395, 1987bPubMedCrossRefGoogle Scholar
  17. Norton L, Simon R. Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treatment Reports 61: 1307–1317, 1977PubMedGoogle Scholar
  18. Peters WP, Davis R, Shpall EJ, Jones RB, et al. Adjuvant chemotherapy involving high-dose combination cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) and autologous bone marrow support (ABMS) for stage II/III breast cancer involving ten or more lymph nodes (CALGB 8782): a preliminary report. Abstract. Proceedings of the American Society of Clinical Oncology 9: 22, 1990Google Scholar
  19. Peters WP, Shpall EJ, Jones RB, Olsen G, Bast RC, et al. Highdose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. Journal of Clinical Oncology 6: 1368–1375, 1988PubMedGoogle Scholar
  20. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. New England Journal of Medicine 316: 1493–1498, 1987PubMedCrossRefGoogle Scholar
  21. Powles TJ, Smith IE, Ford HT, et al. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1: 580–582, 1980PubMedCrossRefGoogle Scholar
  22. Williams SF, Mick R, Dresser R, Golick J. Beschorner J, et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. Journal of Clinical Oncology 7: 1824–1830, 1989PubMedGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Roy B. Jones
    • 1
  • Elizabeth J. Shpall
    • 1
  1. 1.Bone Marrow Transplant ProgramUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations